Barclays
TBPH icon

Barclays’s Theravance Biopharma TBPH Stock Holding History

Barclays’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-112
Closed -$2K – 7254
2014
Q4 		$2K Hold
112
– – ﹤0.01% 7122
2014
Q3 		$3K Sell
112
-112
-50% -$3.25K ﹤0.01% 7330
2014
Q2 		$7K Buy
+224
New +$6.74K ﹤0.01% 7004

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's TBPH Position: Q1 2026 in Review

Barclays reduced its Theravance Biopharma (TBPH) stake by 58% in Q1 2026, selling an estimated $1.15M and leaving 46,376 shares worth $753K. The position accounts for ﹤0.01% of the portfolio, ranked #2930.

Barclays first reported a position in TBPH in Q2 2014 and has held it in 48 quarters since. The position peaked at $2.09M in Q4 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Barclays held 46,376 shares of Theravance Biopharma worth $753K as of Q1 2026.
  • Barclays sold 65,243 Theravance Biopharma shares in Q1 2026, an estimated $1.15M.
  • Theravance Biopharma made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2930 holding.
  • Barclays first reported a position in Theravance Biopharma in Q2 2014 and has held it in 48 quarters since.
  • Barclays's Theravance Biopharma position peaked at $2.09M in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.